2016
Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option
Ashraf M, Souka A, Adelman R, Forster SH. Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. Eye 2016, 30: 1531-1541. PMID: 27564719, PMCID: PMC5177746, DOI: 10.1038/eye.2016.174.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaMacular edemaLarge phase 3 trialsBetter baseline VAEfficacy of afliberceptRole of afliberceptSecondary therapeutic optionsPhase 3 trialProtocol TBaseline VABimonthly regimenNata protocolAnatomic outcomesTherapeutic optionsPoor visionTreatment strategiesPrimary drugAfliberceptDifferent dosesDoseRanibizumabRegimenEdemaPatientsRecent data
2012
Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up
Zebardast N, Adelman RA. Intravitreal Ranibizumab for Treatment of Choroidal Neovascularization Secondary to Angioid Streaks in Pseudoxanthoma Elasticum: Five-year Follow-up. Seminars In Ophthalmology 2012, 27: 61-64. PMID: 22784267, DOI: 10.3109/08820538.2012.680644.Peer-Reviewed Original ResearchConceptsChoroidal neovascularizationOptical coherence tomographyPseudoxanthoma elasticumFluorescein angiographyNeovascular activityTreatment of CNVIntravitreal ranibizumab injectionsFive yearsMacular choroidal neovascularizationLong-term effectivenessOCT evidenceIntravitreal ranibizumabRanibizumab injectionsRanibizumab therapyAffected eyeIntraretinal fluidVisual acuityFluorescein leakageAngioid streaksScar formationInitial injectionCoherence tomographyRanibizumabInjectionNeovascularization
2010
The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage
Latkany P, Duggal M, Goulet J, Paek H, Rambo M, Palmisano P, Levin W, Erdos J, Justice A, Brandt C. The need for validation of large administrative databases: Veterans Health Administration ICD-9CM coding of exudative age-related macular degeneration and ranibizumab usage. Journal Of Ocular Biology, Diseases, And Informatics 2010, 3: 30-34. PMID: 21139706, PMCID: PMC2956455, DOI: 10.1007/s12177-010-9052-4.Peer-Reviewed Original ResearchExudative age-related macular degenerationAge-related macular degenerationExcellent positive predictive valuePositive predictive valuePredictive valueMacular degenerationLarge electronic medical record systemsClinical Modification codingLarge administrative databaseNegative predictive valueElectronic medical record systemVA ConnecticutMedical record systemChart reviewNinth RevisionOphthalmology clinicAdministrative databasesClinical informationInternational ClassificationDistinct patientsTherapy policyRanibizumabPatientsRecord systemDegeneration
2008
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefe's Archive For Clinical And Experimental Ophthalmology 2008, 247: 171. PMID: 18781316, DOI: 10.1007/s00417-008-0936-y.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAptamers, NucleotideBevacizumabChoroidal NeovascularizationDisease Models, AnimalDose-Response Relationship, DrugFluorescein AngiographyInjectionsLight CoagulationMacular DegenerationRanibizumabRatsRats, Inbred BNVascular Endothelial Growth Factor AVitreous BodyConceptsLeakage of CNVTreatment of CNVPegaptanib sodiumChoroidal neovascularizationIntravitreal injectionRat modelBackgroundVascular endothelial growth factorAnti-VEGF agentsEffect of bevacizumabAnti-VEGF medicationsBrown Norway ratsEndothelial growth factorNon-human primatesAngiography 1Histopathologic toxicityIntravitreal bevacizumabCNV leakageFluorescein angiographyLaser photocoagulationBevacizumabTherapeutic effectCNV lesionsRanibizumabDay 1Important stimulator
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply